Artax Biopharma
Latest round
- Series B
Last raised
- May 2022
Total raised
- $29M
Investors
- 5
About Artax Biopharma
Artax Biopharma, Inc.Founded in 2013 and headquartered in Cambridge, US, Artax Biopharma, Inc. is dedicated to the development of therapies for autoimmune diseases. The company operates independently, with no known subsidiaries or parent companies. The CEO and founder, Damia Tormo, has a history of founding and leading companies in the biopharmaceutical sector.Artax Biopharma specializes in developing immunomodulatory therapies, with AX-158 as its primary product. This oral small molecule acts as a Nck modulator, inhibiting Nck binding to the T cell receptor to prevent inappropriate T cell activation by self-antigens. AX-158 has shown promising results in Phase 2a clinical trials for psoriasis and is anticipated to enter Phase 2 trials for atopic dermatitis and other autoimmune conditions in 2025.Artax Biopharma generates revenue through partnerships and clinical trial engagements with healthcare providers and pharmaceutical companies. The company's revenue structure primarily relies on collaborative agreements for the development and commercialization of AX-158 and other products in its pipeline, with revenue derived from milestone payments and potential royalties as products advance through development phases. The company is focused on launching AX-158 for additional autoimmune conditions and aims to initiate further trials in 2025. Additionally, Artax is targeting growth in North American and European markets, enhancing its partnerships and collaborations to drive revenue generation and increase accessibility to its innovative therapies.
Who invested in Artax Biopharma
5 investors across 3 rounds
See all investors in Artax Biopharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Artax Biopharma
Who invested in Artax Biopharma?
Artax Biopharma has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Artax Biopharma raised?
Artax Biopharma has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Artax Biopharma last raise money?
Artax Biopharma's most recent round on record is a Series B, in May 2022.
What does Artax Biopharma do?
Artax Biopharma is a biotechnology company.
Where is Artax Biopharma headquartered?
Artax Biopharma is headquartered in Cambridge, US.
Which VCs invest in companies like Artax Biopharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Artax Biopharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Artax Biopharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.